SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

NEW Required CCTO Orientation Class: Session 8, “Introduction to Informed Consent”

August 8, 2019 - SCI Communications

The CCTO is now offering a new orientation class that is mandatory for new hires and required for all research staff who consent patients.

Orientation Session 8, titled “Introduction to Informed Consent,” is a 60-minute course focusing on the history of informed consent that provides ample opportunities for participants to practice their consenting skills and discuss ethical scenarios. It will be offered once a month in rotation with the current orientation sessions.

The inaugural class will be held Thursday, August 29 from 10:30-11:30am at 800 Welch Road in conference room FC180. A Live Zoom Webinar session will also be available for those who cannot attend in person.

Session 8 will be available for sign up in STARS starting MONDAY, AUGUST 12. To sign up for either the in-person class or the Live Zoom Webinar, search the STARS catalog for “CCTO,” “CCTO-0008-082919,” or “Introduction to Informed Consent”.

For class sign-up assistance, please contact Amanda Sullivan at amanda08@stanford.edu or 650-721-4086. For any other questions, please reach out to ccto-admin@stanford.edu.

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube